Anne R Cappola1, Qian-Li Xue, Linda P Fried. 1. Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Pennsylvania School of Medicine, 415 Curie Blvd, Philadelphia, PA 19104, USA. acappola@mail.med.upenn.edu
Abstract
BACKGROUND: Alterations in anabolic hormones are theorized to contribute to aging and frailty, with most studies focusing on the relationship between individual hormones and specific age-associated diseases. We hypothesized that associations with frailty would most likely manifest in the presence of deficits in multiple anabolic hormones. METHODS: The relationships of serum levels of total IGF-1, DHEAS, and free testosterone (T) with frailty status (nonfrail, prefrail, or frail) were analyzed in 494 women aged 70-79 years enrolled in the Women's Health and Aging Studies I or II. Using multivariate polytomous regression, we calculated the odds of frailty for deficiency in each hormone (defined as the bottom quartile of the hormone) individually, as well as for a count of the hormones. RESULTS: For each hormone, in adjusted analyses, those with the deficiency were more likely to be frail than those without the deficiency, although this did not achieve statistical significance (IGF-1: odds ratio [OR] 1.82, confidence interval [CI] 0.81-4.08; DHEAS: OR 1.68, CI 0.77-3.69; free T: OR 2.03, CI 0.89-4.64). Compared with those with no hormonal deficiencies, those with one deficiency were not more likely to be frail (OR 1.15, CI 0.49-2.68), whereas those with two or three deficiencies had a very high likelihood of being frail (OR 2.79, CI 1.06-7.32), in adjusted models. CONCLUSIONS: The absolute burden of anabolic hormonal deficiencies is a stronger predictor of frailty status than the type of hormonal deficiency, and the relationship is nonlinear. These analyses suggest generalized endocrine dysfunction in the frailty syndrome.
BACKGROUND: Alterations in anabolic hormones are theorized to contribute to aging and frailty, with most studies focusing on the relationship between individual hormones and specific age-associated diseases. We hypothesized that associations with frailty would most likely manifest in the presence of deficits in multiple anabolic hormones. METHODS: The relationships of serum levels of total IGF-1, DHEAS, and free testosterone (T) with frailty status (nonfrail, prefrail, or frail) were analyzed in 494 women aged 70-79 years enrolled in the Women's Health and Aging Studies I or II. Using multivariate polytomous regression, we calculated the odds of frailty for deficiency in each hormone (defined as the bottom quartile of the hormone) individually, as well as for a count of the hormones. RESULTS: For each hormone, in adjusted analyses, those with the deficiency were more likely to be frail than those without the deficiency, although this did not achieve statistical significance (IGF-1: odds ratio [OR] 1.82, confidence interval [CI] 0.81-4.08; DHEAS: OR 1.68, CI 0.77-3.69; free T: OR 2.03, CI 0.89-4.64). Compared with those with no hormonal deficiencies, those with one deficiency were not more likely to be frail (OR 1.15, CI 0.49-2.68), whereas those with two or three deficiencies had a very high likelihood of being frail (OR 2.79, CI 1.06-7.32), in adjusted models. CONCLUSIONS: The absolute burden of anabolic hormonal deficiencies is a stronger predictor of frailty status than the type of hormonal deficiency, and the relationship is nonlinear. These analyses suggest generalized endocrine dysfunction in the frailty syndrome.
Authors: Giorgio Valenti; Licia Denti; Marcello Maggio; GianPaolo Ceda; Stefano Volpato; Stefania Bandinelli; Graziano Ceresini; Anne Cappola; Jack M Guralnik; Luigi Ferrucci Journal: J Gerontol A Biol Sci Med Sci Date: 2004-05 Impact factor: 6.053
Authors: Jeremy Walston; Mary Ann McBurnie; Anne Newman; Russell P Tracy; Willem J Kop; Calvin H Hirsch; John Gottdiener; Linda P Fried Journal: Arch Intern Med Date: 2002-11-11
Authors: Manjinder S Sandhu; Adrian H Heald; J Martin Gibson; J Kennedy Cruickshank; David B Dunger; Nicholas J Wareham Journal: Lancet Date: 2002-05-18 Impact factor: 79.321
Authors: Anne R Cappola; Qian-Li Xue; Luigi Ferrucci; Jack M Guralnik; Stefano Volpato; Linda P Fried Journal: J Clin Endocrinol Metab Date: 2003-05 Impact factor: 5.958
Authors: Sean X Leng; Anne R Cappola; Ross E Andersen; Marc R Blackman; Kathleen Koenig; Michael Blair; Jeremy D Walston Journal: Aging Clin Exp Res Date: 2004-04 Impact factor: 3.636
Authors: Mara A McAdams-DeMarco; Andrew Law; Jingwen Tan; Cassandra Delp; Elizabeth A King; Babak Orandi; Megan Salter; Nada Alachkar; Niraj Desai; Morgan Grams; Jeremy Walston; Dorry L Segev Journal: Transplantation Date: 2015-04 Impact factor: 4.939
Authors: Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen Journal: Endocr Rev Date: 2012-03-20 Impact factor: 19.871
Authors: T Doi; H Makizako; K Tsutsumimoto; R Hotta; S Nakakubo; K Makino; T Suzuki; H Shimada Journal: J Nutr Health Aging Date: 2018 Impact factor: 4.075
Authors: M Maggio; G P Ceda; F Lauretani; C Cattabiani; E Avantaggiato; S Morganti; F Ablondi; S Bandinelli; L J Dominguez; M Barbagallo; G Paolisso; R D Semba; L Ferrucci Journal: Int J Androl Date: 2011-06-15
Authors: Grace Huang; Shehzad Basaria; Thomas G Travison; Matthew H Ho; Maithili Davda; Norman A Mazer; Renee Miciek; Philip E Knapp; Anqi Zhang; Lauren Collins; Monica Ursino; Erica Appleman; Connie Dzekov; Helene Stroh; Miranda Ouellette; Tyler Rundell; Merilyn Baby; Narender N Bhatia; Omid Khorram; Theodore Friedman; Thomas W Storer; Shalender Bhasin Journal: Menopause Date: 2014-06 Impact factor: 2.953
Authors: Mara A McAdams-DeMarco; Jingwen Tan; Megan L Salter; Alden Gross; Lucy A Meoni; Bernard G Jaar; Wen-Hong Linda Kao; Rulan S Parekh; Dorry L Segev; Stephen M Sozio Journal: Clin J Am Soc Nephrol Date: 2015-11-16 Impact factor: 8.237